Precision Medicine in the Prostate Cancer Care Pathway
Recruiting · NCT04763317 · Observational (researchers observe without assigning treatment) · Lead sponsor: Institute of Cancer Research, United Kingdom
View the official record on ClinicalTrials.gov →Interventions studied
Prostate cancer risk gene panel
What this trial is about
This study aims to evaluate the use of a prostate cancer specific predisposition genetic panel test in men with / at high risk of prostate cancer. The genetic test will analyse men's DNA samples for the presence of mutations in rare genes as well as common genetic variation to provide men with information about their risk of prostate cancer. This study will evaluate the clinical impact of the test on risk assessment and clinical management in terms of screening and treatment.
Who can take part
Age range
30 Years to 70 Years
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Affected cohort:
- Affected with PrCa \< 60 years or
- Affected with metastatic castration resistant PrCa (mCRPC) at any age or Aggressive PrCa Gleason 4+4 or higher \<70 years
- Affected with family history defined as three or more cases any age (FDR or SDR)
- Unaffected cohort: (This cohort is no longer recruiting, it has completed recruitment)
- Aged \>30 and with a family history defined as:
- FDR diagnosed \< 70
- 2 or more cases in First or Second Degree Relatives (FDR/SDR) with one case diagnosed \< 70 years
- 3 or more cases at any age (on same side of family)
Exclusion criteria
- • WHO performance status 4
Where it is running
1 location listed.
- Royal Marsden Hosital, - Sutton, England, United Kingdom